Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients. Black GS, Huang X, Qiao Y, Tarapcsak S, et al. Blood 2022;140:401-405.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Black GS, Huang X, Qiao Y, Tarapcsak S, et al. Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients. Blood 2022;140:401-405.
PMID: 35476648